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Introduction
Timed degradation of cellular regulatory proteins by the
ubiquitin pathway plays a critical role in controlling cellular
growth and proliferation. Substrates of this pathway
include tumor suppressors, cell cycle proteins, transcrip-
tion factors, and tyrosine kinase receptors, among others.
Proteolysis of many of these regulators is controlled by
ubiquitin ligases, the substrate specificity of which is dic-
tated by different F-box proteins that act as substrate
recognition factors. Substrates are recognized and bound
by the F-box protein subunits only when they are phospho-
rylated on specific sites.
Because ubiquitination of critical proteins occurs in a
tissue-specific and time-regulated manner, the use of
animal models becomes critical in the identification of sub-
strates that are involved in cell cycle regulation, apoptosis,
and development, which cannot be studied in vitro. An
interesting model for the study of general ubiquitination in
vivo was recently described [1], in which transgenic mice
were made to overexpress a fusion of the human ubiquitin
gene (Ubc) and the enhanced green fluorescent protein.
The epitope-tagged ubiquitin is first expressed as early as
the morula stage in embryonic development, without any
effect on viability. In adult mice the transgene is expressed
Turnover of several regulatory proteins results from targeted destruction via ubiquitination and
subsequent degradation through the proteosome. The timely and irreversible degradation of critical
regulators is essential for normal cellular function. The precise biochemical mechanisms that are
involved in protein turnover by ubiquitin-mediated degradation have been elucidated using in vitro
assays and cell culture systems. However, pathways that lead to ubiquitination of critical regulatory
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efficacy of drugs designed to inhibit or enhance protein turnover by ubiquitination requires in vivo
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proteins that are known either to be regulated by ubiquitin-mediated degradation or to have a catalytic
function in this process, and to play an important role in breast cancer. We outline the functions of
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from cell-free in vitro data or from experiments conducted in cell culture systems.
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in virtually all tissues. These mice represent a powerful tool
for the recovery of as yet unknown substrates that are
ubiquitinated  in vivo. In contrast, the models described
below target proteins that are known to regulate or to be
regulated by the ubiquitin–proteosome system, and to
play a role in breast carcinomas.
The cyclin-dependent kinase inhibitor p27
The ubiquitin–proteosome pathway plays a major role in
the turnover of cell cycle regulatory proteins. Loss of the
p27 protein – a cyclin-dependent kinase inhibitor – may
contribute to uncontrolled proliferation. In several human
cancers, including breast cancer, targeted inactivation of
p27 is associated with aggressive behavior (for review
[2]). Human Skp1 and the F-box protein Skp2 were origi-
nally identified as two proteins that physically interact with
cyclin A, and are therefore designated as S-phase kinase-
associated proteins [3]. In both yeast and humans, a
protein ubiquitin ligase system known as Skp1/Cul1/F-box
(SCF) complex targets a number of proteins for ubiquitin-
mediated proteolysis in a phosphorylation-dependent
manner. In this complex, the F-box protein determines the
substrate specificity. Skp2 is the F-box protein required for
the ubiquitination and consequent degradation of phos-
phorylated p27 [4–6].
Whereas p27 knockout mice develop generalized hyper-
plasia and spontaneous pituitary tumors [7–9], Skp2-defi-
cient mice grow slower than do littermate controls and
have smaller organs, with all tissues containing decreased
numbers of cells [10]. Interestingly, all cellular and
histopathologic abnormalities observed in Skp2-deficient
mice are abolished in Skp2/p27 double knockout mice,
indicating that p27 is a primary substrate of Skp2 in vivo
(K Nakayama, personal communication). Several in vitro
studies indicated an inverse functional relationship
between p27 and Skp2, and in vivo data in part confirm
those findings. Skp2 transgenic mice targeted to the T-
lymphoid lineage demonstrated a cooperative oncogenic
effect when crossed with activated N-ras transgenic mice
[11]. These double transgenic mice developed tumors
with shorter latency and higher penetrance as compared
with N-ras transgenic animals. Interestingly, no change in
p27 phosphorylation was observed in transgenic mice,
suggesting that some other component may be a limiting
factor for p27 destruction. That study demonstrated the
oncogenic potential of Skp2 in vivo and provided a unique
tool for the evaluation of functional interactions of this
ubiquitin ligase with other proto-oncogenes.
We recently demonstrated that Skp2-positive cells in
human breast carcinomas represent a subpopulation of
proliferating tumor cells [12]. However, approximately one-
third of breast carcinomas with low proliferative rates
display low p27 levels despite the absence of Skp2.
These data suggest that an alternative mechanism leading
to proteosomal degradation of p27 may be operative in
this subset of breast carcinomas with low proliferative
rates. Malek et al. [13] utilized an interesting approach to
investigate the role of p27 ubiquitination in vivo. Those
investigators genetically engineered a ‘knock in’ of a non-
phosphorylatable mutant of p27, in which the critical thre-
onine residue (the phosphorylation of which is required for
substrate recognition by Skp2) is mutated to alanine
(p27T187A). The surprising finding was that there is a pro-
teolytic pathway that controls p27 degradation in G1,
before the activation of the cyclin E–cyclin dependent
kinase 2 complex, whereas p27T187A was stable in S-
phase, with a half-life similar to that in quiescent cells.
Findings in that in vivo model confirmed the in vitro data
[14] and pointed to the fact that p27 inactivation via
degradation appears to switch from being mitogen depen-
dent in G1 to mitogen independent in the DNA replication
phase of the cell cycle. Malek et al. also proposed the
existence of phosphorylation sites other than those that
may mediate Skp2–p27 interaction. More recently, the
ubiquitin ligase responsible for the G0/G1 degradation of
p27 has been identified. This protein, namely G1-phase
Kip1 ligase (GKL) 1/2, does not appear to require phos-
phorylation either on T187 or S10 (N Nakayama, personal
communication) to accomplish the degradation of p27. It
remains to be proven whether, in human breast cancer,
these two mechanisms of p27 inactivation are operative in
tumor cells that do and in those that do not express Skp2.
This would have considerable therapeutic implications.
Androgen regulation of p27 levels has been suggested by
experiments conducted in cell culture systems. Although
both p27 and p21 have been shown to be degraded by
the proteosome, in a rat model of prostate castration and
testosterone-mediated regeneration we determined that
ubiquitin-mediated degradation of p27, but not that of
p21, is under androgen control [15]. Androgen induction
of p21 occurred at the transcriptional level, with no
change in ubiquitin-mediated degradation. In addition,
peak epithelial cell proliferation and maximal p27 protein
levels were unexpectedly achieved simultaneously during
regeneration. Utilizing this in vivo model, we determined
that androgen action was both differentiating (with stabi-
lization of p27 protein through inhibition of proteosomal
degradation in the majority of prostate epithelial cells) and
proliferating (via the induction of p27 degradation in prolif-
erating epithelial cells). That study provided evidence of a
previously unrecognized level of complexity in the in vivo
regulation of critical cyclin-dependent kinase inhibitors
(CKIs) by androgens. We recently demonstrated that
Skp2 and p27 are modulated by the proliferative action
induced by estrogens in breast cancer cells [12], and it
would therefore be interesting to test the hypothesis that
the same mechanisms elucidated in the prostate are oper-
ative in breast epithelium as well, utilizing models of breast
regeneration. In addition, because Skp2 inhibitors may18
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soon be ready for testing, animal models such as the ones
described above represent ideal tools to determine the
specificity and efficacy of such compounds.
Wnt-1/β β-catenin pathway
β-Catenin is an important cellular regulator that is involved
in the control of growth and development, as well as
cell–cell adhesion (for review [16]). A pool of β-catenin is
present in the cytoplasm bound to Apc, the product of the
tumor suppressor gene adenomatous polyposis coli [17],
which facilitates phosphorylation of β-catenin and its sub-
sequent ubiquitination by an SCF complex. Thus, β-
catenin is constitutively degraded in the cytoplasm, but in
response to activation of the Wnt pathway β-catenin phos-
phorylation is inhibited and degradation of β-catenin
decreases. Consequently, β-catenin accumulates and
migrates into the nucleus, where it binds to a transcription
factor of the Lef-1/Tcf-1 family to induce the expression of
target genes [18,19]. Importantly, two of those target
genes encode proto-oncoproteins, namely c-Myc and
cyclin D1 [20–22]. Genetic mutations or altered protein
expression of β-catenin and Apc have been implicated in
human cancers, and all result in increased β-catenin
levels, which in turn lead to increased Lef-1/Tcf-1 tran-
scriptional activity and deregulated proliferation [23]. In
several malignancies, increased levels of β-catenin have
been shown to be due to β-catenin mutations that abolish
phosphorylation sites essential for its degradation [16,24].
Furthermore, Wnt-1, which induces stabilization of β-
catenin, was first identified as a proto-oncogene frequently
activated by retroviral insertion of mouse mammary tumor
virus (MMTV) into the Wnt-1 locus in mouse mammary
tumors. Wnt is a positive regulator of β-catenin, leading to
stabilization of β-catenin and allowing its migration from the
cytoplasm to the nucleus. Thus, wild-type and mutated
forms of β-catenin acquire oncogenic properties when they
accumulate because of a defect in degradation. The F-box
protein that determines substrate specificity for the E3
ligase involved in β-catenin ubiquitination is β-TrCP [25].
Transgenic mouse models show that β-catenin leads to
hair follicle tumors when overexpressed in epidermal cells
[26] and to colon adenomas when overexpressed in the
intestines [27]. Attractive animal models have been engi-
neered to investigate the in vivo functions of the β-catenin
pathway in the mouse mammary gland. In one of these,
namely ∆N89 β-catenin transgene, which cannot undergo
degradation and accumulates in the cytoplasm, is driven
by the MMTV long terminal repeat to luminal cells of
mammary and salivary glands [28]. MMTV–∆N89  β-
catenin transgenic mice, even at an early stage of puberty,
develop lobular–alveolar hyperplasia, which is normally
associated with hormonal stimulation in late pregnancy.
Importantly, MMTV–∆N89  β-catenin transgenic mice
develop breast cancer with 100% penetrance. In contrast,
the phenotype of mammary gland in MMTV–Wnt-1 trans-
genic mice is characterized by ductal hyperplasia with a
feathery, hyperbranched pattern, which is reminiscent of
the morphologic features of the mammary gland during
early pregnancy [28,29]. In addition, mammary adenocar-
cinomas arise in approximately 50% of female transgenic
mice by 6 months of age [29].
The influence of estrogenic hormones on β-catenin/Wnt-
1-induced tumors is also of interest. Because breeding
females of MMTV–∆N89  β-catenin and MMTV–Wnt-1
transgenic mice develop tumors slightly earlier than do
virgin ones, it has been proposed that estrogen may
increase the oncogenicity of both Wnt-1 and β-catenin.
However, it is not possible to exclude that the acceleration
of tumor formation in the breeding females may depend on
the increased mass of the mammary gland. Interestingly, in
MMTV–Wnt-1 transgenic/estrogen receptor (ER) knock-
out mice and in ovariectomized MMTV–Wnt-1 transgenic
mice, ductal hyperplasia and tumors continue to form,
albeit with delayed onset, suggesting that the Wnt-1
transgene does not require estrogen to induce mammary
hyperplasia and tumors [29]. These compelling models
support the hypothesis that a fraction of ER-negative
estrogen-independent breast cancers may originate
directly from ER-α-negative cells, rather than from ER-α-
positive cells, which later undergo ER loss.
Animal models have been also used to explore β-catenin
downstream targets. Wild-type mice do not express signif-
icant levels of cyclin D1 mRNA until mid-pregnancy,
whereas northern blot analysis reveals high levels of cyclin
D1 as well as c-Myc mRNA in virgin MMTV–∆N89  β-
catenin transgenic mice [28]. Moreover, cyclin D1-null
mice are characterized by hypoplastic lobular–alveolar
structures, with a normal side branching pattern [30],
whereas MMTV–cyclin D1 transgenic mice and MMTV–c-
myc trangenic mice develop lobular–alveolar hyperplasia
in perfect concordance with the early phenotype of
MMTV–∆N89  β-catenin transgenic mice [31]. Interest-
ingly, these transgenic mice develop mammary gland car-
cinomas with slower kinetics than do MMTV–∆N89
β-catenin transgenic mice, providing evidence that β-
catenin concurrently elevates both cyclin D1 and c-myc
proto-oncogenes.
Although the activation of the Wnt-1/β-catenin pathway is
well established in a subset of human breast cancers,
increased susceptibility to mammary neoplasia has not
been reported to date in the human syndrome associated
with mutations in the APC gene. In contrast, 20% of mice
carrying  ApcMin (Min), a nonsense mutation of Apc,
develop mammary tumors, as well as intestinal adenocar-
cinomas [32]. Because the life-span of these transgenic
mice is very short, study of the effects of chemical carcino-
gens on Min/+ mice and the use of transplants from Min/+
treated mice have better highlighted the increased sus-19
ceptibility of these mice to mammary tumors. Although
Apc mutations appear to have an additional effect on
breast epithelial transformation in mice, which is in con-
trast to humans, the possibility that the high background
rate of mammary tumors in the population may hide the
increased risk for breast cancer in human carriers of APC
mutations cannot be ruled out.
The protein kinase CK2 promotes Wnt signaling [33]. His-
tologic abnormalities in the mammary gland, such as retar-
dation of development, incomplete involution after
lactation, and dysplastic squamous and alveolar lesions,
have been found in half of MMTV–CK2α transgenic mice
[34]. Moreover, over a period of 2 years 30% of these
transgenic mice developed mammary tumors, specifically
glandular, adenosquamous, scirrous, and sarcomatoid car-
cinomas. The long latency suggests a multistep pathway
in CK2α-induced tumorigenesis, whereas the wide spec-
trum of tumor histotypes supports the existence of several
cooperating CK2α downstream targets. Furthermore, high
protein levels of β-catenin and c-Myc are detected in
these tumors, confirming the emerging role of CK2α as a
positive regulator of the Wnt-1/β-catenin pathway [33].
The ubiquitin ligase MDM2
Originally cloned from a tumorigenic mouse cell line,
which contains amplified DNA sequences in the form of
double minutes [35], MDM2 is amplified and/or overex-
pressed most frequently in sarcomas [36] but also in other
tumors, including breast carcinomas [37]. Mdm2 gene
transforms immortalized mouse NIH3T3 cells and rat
embryo fibroblasts when transfected alone and cotrans-
fected with activated ras gene, respectively [35,38]. Its
oncogenicity is mainly attributed to its interaction with
p53, a transcription factor with known tumor suppressor
functions. MDM2 binds to the activation domain of p53,
with consequent inhibition of its transcriptional activity,
and exports p53 into the cytoplasm and targets it for pro-
teosome-mediated degradation through its well known E3
ligase activity [36]. Because MDM2 is itself a transcrip-
tional target of p53, MDM2 and p53 are coordinately
modulated and ensure proper protection from DNA
damage. MDM2 is also negatively regulated by the tumor
suppressor protein p14ARF. Arf directly associates with
MDM2 and blocks its ability to interact with p53. Because
human MDM2 is overexpressed in 5–10% of human
tumors and ARF is silenced in many others, disruption of
the ARF–Mdm2–p53 axis is common in cancers [39]. The
hypothesis that the MDM2-mediated negative regulation
of p53 accounts for MDM2 oncogenicity is also supported
by the evidence that in most human sarcomas either a p53
mutation or MDM2 amplification is detected [40].
However, splice variants of MDM2 that lack the p53-
binding site maintain their ability to transform NIH3T3 cells
[41], suggesting the existence of other p53-independent
MDM2 oncogenic pathways. These may involve other cell
cycle regulators that have been shown to bind to MDM2,
such as E2F1, pRb, and p107 [36].
Several studies conducted in animal models, summarized
in Table 1 [42–46], have investigated the interaction
between MDM2 and p53 in vivo and other possible p53-
independent MDM2 pathways. Specifically, studies in
Mdm2-null mice point to the importance of MDM2 in
tumorigenesis, mainly as a p53-negative regulator. Mdm2-
null mice die early in development, whereas double
homozygous Mdm2/p53 mutant mice are viable, providing
evidence that, in early mouse development, MDM2 is
required to inhibit p53-mediated cell cycle arrest and
apoptosis [42].
In contrast, experiments conducted in transgenic mice with
overexpression of MDM2 not confined to particular tissues
support the hypothesis of a p53-independent function of
MDM2. Because constitutively high levels of MDM2 affect
early embryonic development, transgenic chimeras were
generated from a stem cell line expressing low levels of
transgenic  Mdm2 transcript [43]. Interestingly, these
Mdm2-transgenic mice, when compared with p53-null
mice, develop tumors at a slower rate and show a some-
what different histologic spectrum, with an increase in the
number of sarcomas. This peculiar tumor spectrum, which
is also retained in a p53-null background, suggests that the
MDM2 pathway is at least partly p53 independent.
Additional in vivo studies have been focused on tissue-
specific expression of MDM2. The Mdm2-transgene,
driven by the β-lactoglobulin promoter, is directed exclu-
sively at the pregnant and lactating mammary gland
[44,45]. These transgenic mice display lactation defects,
with a decreased number of lobules paradoxically accom-
panied by ductal hyperplasia with atypical epithelial cells
with multiple, large hyperchromatic nuclei. MDM2 induces
cyclin A overexpression in these cells, leading to repetitive
rounds of DNA replication not followed by mitosis, with
consequent cellular polyploidy. In addition, after a long
period of latency, a small subset of these Mdm2-trans-
genic mice develop ductal carcinomas of the breast. The
atrophic/dysplastic breast phenotype is not suppressed
when  Mdm2-transgenic mice are crossed with p53-null
[44] or E2F1-null mice [45] and is not enhanced when
Mdm2-trangenics are crossed with E2F1-trangenic mice
[45]. These findings suggest a p53- and E2F1-indepen-
dent function of MDM2 in breast.
Targeted MDM2 overexpression in the basal layer of the
epidermidis, using a human cytokeratin K14 promoter,
produces an early and transient phenotype, characterized
by altered expression of selected cytokeratins, high level
of proliferation, and increased apoptosis [46]. Paradoxally,
this phenotype is abolished in a p53-null background. In
addition, in the Mdm2-transgenic mice the induction of
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p53 and p21 after ultraviolet exposure is decreased. Inter-
estingly, later in life, one-third of Mdm2-transgenic mice
develop hyperplastic/dysplastic skin lesions and, in a small
percentage, skin carcinomas. These data point to a
complex interaction between MDM2 and p53 in the skin
that is different from that which occurs in breast epithelium.
MDM2 inactivation in vivo results in tumor-suppressor
activity in a dose-dependent manner in nude mice bearing
MCF-7 or MDA-MB-468 breast carcinoma xenografts
[47]. In both of these in vivo models, synergistic or addi-
tive therapeutic effects of MDM2 inhibition with several
clinically used chemotherapeutic agents were observed,
suggesting that MDM2 inhibitors may have a broad spec-
trum of tumor suppressor activities in human breast
cancers, regardless of p53 status.
Thus, these animal models appear to confirm the onco-
genicity of MDM2 in vivo and suggest the existence of
diverse mechanisms of action that appear to be
tissue/organ specific.
The ubiquitin ligase E6-associated protein
Originally discovered because of its ability to target p53
for degradation by the proteosome in association with the
human papillomavirus E6 protein [48], E6-associated
protein (E6-AP) was later found to be a nuclear hormone
receptor coactivator [49]. The genomic locus that
encodes E6-AP is mutated in Angelman syndrome, a neu-
rologic human disorder that is characterized by motor dys-
function and mental retardation [50]. Consistent with this
finding, heterozygous E6-AP-null mice show neurologic
defects and decreased expression levels of E6-AP in the
hippocampal neurons and in the Purkinje cells of the cere-
bellum, with consequent increase in p53 levels [51].
These data suggest that it is the E3-ligase function of E6-
AP that is involved in the pathogenesis of Angelman syn-
drome, caused by uniparental disomy of chromosome 15,
and characterized by mental retardation, ataxia, seizures,
and inappropriate laughter.
Interestingly, E6-AP is overexpressed in spontaneous
mouse mammary tumors and its expression is inversely
related to ER and progesterone receptor (PR) expression
[52]. These tumors, in fact, do not express ER and PR.
Moreover, tissue extracts from these tumors show that E6-
AP maintains its catalytic ability to ubiquitinate an artificial
substrate, although the levels of its well known substrate
p53 do not inversely correlate with E6-AP levels. More
recently, it has been shown that mammary gland growth in
response to estrogen and progesterone administration is
not decreased in homozygous E6-AP-null mice [53].
Taken together, these data suggest that the ER and PR
coactivator function of E6-AP is not required to mediate
estrogen and progesterone action on mammary gland. In
contrast, prostate growth induced by testosterone admin-
istration and uterine growth induced by estradiol adminis-
tration were attenuated, and gonad size was reduced in
these homozygous E6-AP-null mice. The authors specu-
lated the compelling possibility that the role of E6-AP in
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Table 1
Comparison of genetic alterations of MDM2 in different genetic backgrounds
E6-AP- Hypothetical 
Phenotype p53-null  E6-AP-null  transgenic  MDM2 
MDM2-mutant mice (major features) background background background pathway Reference
MDM2 null Not viable Viable NR NR p53 dependent [42]
MDM2 transgenic In comparison with p53–/–: NR NR p53-independent [43]
Slow rate of tumorigenesis Increased rate of 
tumorigenesis
Increased number of sarcomas No changes*
MDM2 transgenic  Atrophic/dysplastic  No changes* No changes* No changes* p53/E6-AP  [44,45]
(mammary gland) phenotype of mammary gland independent
Ductal carcinoma (long  NR NR NR
latency)
MDM2 transgenic  Scaly skin with increased  NR NR NR p53 dependent [46]
(basal layer  thickness of epidermidis
epidermidis) Altered K14 and K6  Normal K14 
expression and K6 expression
Increased Ki67 and  Normal Ki67 
TUNEL+ cells and TUNEL stains
Epidermal hyperplasia  NR
dysplasia and cancer 
(long latency)
*No changes detected in the crossed mice in comparison with the MDM2-mutant mice. NR, not reported.21
the mouse mammary gland tumorigenesis may depend on
its E3-ligase activity, involve the turnover of ER and PR,
and play an important role in the acquisition of hormone
independency.
Conclusion
The ubiquitin–proteosome pathway is an important mech-
anism for irreversible elimination of critical cell regulatory
proteins. A great deal of information on its function and
interaction has been gained from yeast and mammalian
cell systems. Mouse models are greatly expanding our
knowledge of tissue-specific and temporal mechanisms of
action of this pathway in physiologic states, disease, and
development. These models will provide invaluable
insights into the involvement of the ubiquitin–proteosome
pathway in oncogenesis, and constitute models for testing
novel therapeutics directed at enhancing or inhibiting
ubiquitination of critical proteins involved in cancer.
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